Pacira BioSciences and the Pending Class Action
Pacira BioSciences, Inc. (NASDAQ: PCRX) is currently facing a class action lawsuit that calls the attention of investors. The Gross Law Firm has notified shareholders regarding the implications of this legal situation, particularly after alarming news about the company’s patent.
Understanding the Class Period and Allegations
The timeframe for the class action spans from early August 2023 to early August 2024. The lawsuit relates to the company's patent for Exparel, a key product that substantially contributes to Pacira's revenue, accounting for nearly 80% of its income. Following a court decision on this patent's validity, shareholders may have substantial concerns.
What Happened with the Patent?
On August 9, a significant press release disclosed that a court found Pacira’s U.S. Patent No. 11,033,495 to be invalid. This ruling means that eVenus, a competitor, is not infringing this patent, which creates uncertainties about the future for Pacira BioSciences. The invalidity of this essential patent raises questions about other patents held by the company and may expose the company to increased competition in the market.
Stock Price Reaction
The market responded sharply to the news. Pacira's stock price fell dramatically, from a closing price of $22.36 per share on August 8 to a low of $11.70 on August 9, marking a drastic 47% reduction in a single day. Such a decline reflects investors’ apprehension following the patent ruling, prompting many to consider whether to join the class action suit.
Deadlines and Next Steps for Investors
Shareholders interested in participating in the class action must act soon, as the deadline for registering as a lead plaintiff is March 14, 2025. Engaging with this process could help investors recover losses incurred during the tumultuous period impacted by the court ruling.
Benefits of Registration
Once registered, shareholders will gain access to a comprehensive portfolio monitoring system. This service is designed to provide regular updates throughout the class action proceedings. Importantly, registering comes at no cost to the participant.
Why Choose Gross Law Firm?
The Gross Law Firm has established a reputation as a leading national class action law firm. They focus on upholding the rights of investors who might suffer due to unethical business tactics, including fraud and misrepresentation. Their commitment to protecting shareholders' interests is evident, aiming to recover losses sustained by investors during this turbulent time at Pacira BioSciences.
Contact Information for Shareholders
For those wishing to learn more or seek assistance, the Gross Law Firm is available for inquiries. Their office is located on West 38th Street in New York City. Investors can reach out via the phone for further discussions about the current class action and how to participate. Direct email contact details can be provided upon inquiry.
Frequently Asked Questions
What is the class action lawsuit about?
The lawsuit is focused on allegations related to the invalidation of Pacira's key patent, impacting its stock performance and shareholder rights.
Who is eligible to join the class action?
Shareholders who purchased shares of Pacira BioSciences during the specified class period are encouraged to join.
What are the potential outcomes of the lawsuit?
Investors may have a chance to recover losses depending on the proceedings and eventual outcome of the class action.
Is there a cost to participate in the lawsuit?
No, there is no cost or obligation for shareholders who register to participate in the class action.
How can I stay updated on the lawsuit?
By registering, shareholders will receive updates through a dedicated monitoring system provided by the legal team handling the class action.
